



July 27, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Organizational and Personnel Changes

July 27, 2022 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the following organizational and personnel changes.

1. Organizational Changes

The Production Division will be reorganized by function, shifting to an organizational structure around an axis of highly advanced specialization. This reorganization will achieve enables streamlined duties to be handled and build a robust manufacturing system to support globalization.

The Production Strategy Unit will be established to consolidate planning and supply management functions in the Production Division.

The Production Management Dept. will be reorganized into **the Production Management Unit** to undertake appropriate manufacturing planning, purchasing, negotiation and storage operations. In addition, as a result of reviewing the functions of the Logistics Management Dept., its functions will be absorbed into the Production Division.

The newly established **the HSE* & Maintenance Unit** will comprehensively integrate the manufacturing control functions, such as occupational safety and health, facility maintenance and other operations, of each unit with the objective of aligning manufacturing management operations and strengthening the organization. ※Health, Safety, Environments

To enable flexible manufacturing, the existing active pharmaceutical ingredients (API) and formulation units will be reorganized by similar function and the following three manufacturing units will be newly established:

The Formulation Unit will have the function of manufacturing formulation, **the Single Use Technology Unit** will have the function of manufacturing API with single use technology, and **the Core Production Unit** will have the function of manufacturing of long-term listed products.

2. Personnel Changes

Name	New Title	Current Organization
Nobuyuki Tanaka	Director, Production Strategy Unit, Production Division	Director, Production Division
Kiyoji Onishi	Director, Production Management Unit, Production Division	Director, Production Management Dept., Production Division

Kenji Isokawa	Director, HSE & Maintenance Unit, Production Division	Director, Seishin Production Unit, Production Division
Yasushi Zenitani	Director, Single Use Technology Unit, Production Division	Director, Kobe API Unit, Production Division
Yukihiro Kuromoto	Director, Core Product Unit, Production Division	Director, Murotani API Unit, Production Division

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 47-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

###